Femasys Inc Dossier - Source-backed chat

Femasys Inc

FEMYNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.10Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $17.6M

Enterprise Value $11.5M

Shares Outstanding 8.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Femasys Inc. is a commercial-stage biomedical innovator focused on developing and commercializing minimally invasive, in-office therapeutic and diagnostic solutions for women's reproductive health. The company's portfolio is anchored by FemaSeed (an FDA-cleared first-line intratubal insemination treatment for infertility) and FemBloc (a non-surgical permanent birth control system currently in the FINALE pivotal clinical trial). While Femasys has achieved significant clinical, regulatory, and commercial milestones—including growing sales and expanding international distribution—it faces substantial financial risks. The company continues to operate at a net loss, carries an accumulated deficit of approximately $145.0 million, and has a limited cash runway expected to fund operations only into the third quarter of 2026. Additionally, the company must regain compliance with Nasdaq's minimum bid price requirement by July 13, 2026. Consequently, a 'Hold' recommendation is advised, balancing the high-growth potential of its innovative product suite against immediate liquidity and listing compliance risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$21.00

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.3720%

The bear case is triggered by a failure to secure additional financing, leading to severe liquidity constraints as cash is depleted in the third quarter of 2026. Delays in patient enrollment for the FemBloc FINALE trial or slower-than-expected commercial adoption of FemaSeed due to reimbursement hurdles would depress revenue growth. Furthermore, if the company fails to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the July 13, 2026 deadline and is delisted, or if a highly dilutive reverse stock split severely damages shareholder value, the stock would face significant downward pressure.

Base CaseCentral scenario

$3.1755%

The base case assumes steady commercial execution of FemaSeed and gradual enrollment in the FemBloc clinical trial. Sales continue to grow, driven by initial commercial use of FemaSeed Complete and established international distribution partnerships. However, the company remains pre-profitable and requires additional capital to fund operations beyond the third quarter of 2026, leading to moderate shareholder dilution through ATM offerings or structured financing. The company successfully regains Nasdaq compliance, potentially through a reverse stock split, and continues its clinical development pathway with a projected breakeven timeline around 2028.

Bull CaseUpside scenario

$10.0025%

The bull case is driven by rapid commercial adoption of FemaSeed Complete and successful enrollment in the FemBloc FINALE pivotal trial. FemaSeed addresses a multi-billion-dollar global infertility market by enabling OB/GYNs to deliver first-line, in-office treatment, bypassing high-cost specialty IVF clinics. Favorable insurance reimbursement, supported by the newly approved Category III CPT code effective January 1, 2027, accelerates U.S. physician adoption. International expansion through partnerships in Israel, Switzerland, and Europe further boosts top-line growth. Successful completion of the FemBloc trial leads to FDA approval, positioning Femasys as the sole provider of a non-surgical permanent birth control solution, driving exponential revenue growth and path to profitability by 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Innovative, patent-protected product portfolio addressing significant unmet needs in women's reproductive health.
FemaSeed is FDA-cleared and actively commercializing, offering a lower-cost, in-office alternative to IVF.
FemBloc is in a pivotal clinical trial (FINALE) with a clear regulatory pathway toward potential U.S. FDA approval.
Established international distribution partnerships expanding market access in Europe, Israel, and Switzerland.
Approved Category III CPT code for FemaSeed ITI establishes a clear pathway for future U.S. reimbursement.

Key Investment Risks

Going concern risk with cash resources expected to fund operations only into the third quarter of 2026.
Substantial historical losses with an accumulated deficit of approximately $145.0 million as of March 31, 2026.
Nasdaq listing non-compliance risk with a deadline of July 13, 2026, to regain the minimum $1.00 bid price.
Potential for significant shareholder dilution from future capital raises or ATM stock offerings.
Adoption and commercialization risks dependent on physician training and insurance reimbursement timelines.

Thesis Invalidation Triggers

Failure to secure additional funding or capital partners before cash depletion in Q3 2026.
Delisting from the Nasdaq Capital Market due to failure to meet the minimum bid price requirement.
Clinical trial holds, safety concerns, or failure to meet primary endpoints in the FemBloc FINALE pivotal trial.
Slower-than-expected commercial adoption or failure to secure widespread insurance reimbursement for FemaSeed.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.